Sumatriptan

Preview FDA label, NorthStar RxLLC, oral, effective 2025-11-20. Full label on DailyMed

Quoted from the FDA label. Product labels differ by manufacturer and change over time; confirm against the label for the product you are using. Not yet reviewed by a ClinDose pharmacist.

Dosing in kidney impairment

Renal Impairment Sumatriptan and naproxen sodium tablets are not recommended for use in patients with creatinine clearance less than 30 mL/min. Monitor the serum creatinine or creatinine clearance in patients with mild (CrCl = 60 to 89 mL/min) or moderate (CrCL = 30 to 59 mL/min) renal impairment, preexisting kidney disease, or dehydration [see Warnings and Precautions and Clinical Pharmacology] .

Dosing in liver impairment

Dosing in Patients with Hepatic Impairment Sumatriptan and naproxen sodium tablets are contraindicated in patients with severe hepatic impairment [see Contraindications, Use in Specific Populations, Clinical Pharmacology] . Use the lowest effective dosage for the shortest duration consistent with individual patient treatment goals [see Warnings and Precautions] .

Preparation and administration

Administration Information Sumatriptan and naproxen sodium tablets may be administered with or without food. Tablets should not be split, crushed, or chewed.

Calculators for sumatriptan